|Videos|May 2, 2022
Venetoclax in Combination with Carfilzomib for Multiple Myeloma Treatment
Author(s)Shaji Kumar, MD, Jonathan L. Kaufman, MD
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Oncologists discuss the use of carfilzomib for multiple myeloma and their typical treatment regimens of choice.
Advertisement
Episodes in this series
Advertisement
Related to this article
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
4
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
5